NO920854L - Fremgangsmaate og sammensetninger for ikke-invasiv dose til effekt-administrering av lipofile medikamenter - Google Patents

Fremgangsmaate og sammensetninger for ikke-invasiv dose til effekt-administrering av lipofile medikamenter

Info

Publication number
NO920854L
NO920854L NO92920854A NO920854A NO920854L NO 920854 L NO920854 L NO 920854L NO 92920854 A NO92920854 A NO 92920854A NO 920854 A NO920854 A NO 920854A NO 920854 L NO920854 L NO 920854L
Authority
NO
Norway
Prior art keywords
patient
lollipop
dose
compositions
lipofile
Prior art date
Application number
NO92920854A
Other languages
English (en)
Norwegian (no)
Other versions
NO920854D0 (no
Inventor
Theodore Stanley
Brian Hague
Original Assignee
Univ Utah Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found filed Critical Univ Utah Res Found
Publication of NO920854D0 publication Critical patent/NO920854D0/no
Publication of NO920854L publication Critical patent/NO920854L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO92920854A 1989-09-05 1992-03-04 Fremgangsmaate og sammensetninger for ikke-invasiv dose til effekt-administrering av lipofile medikamenter NO920854L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1989/003801 WO1991003233A1 (en) 1989-09-05 1989-09-05 Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs

Publications (2)

Publication Number Publication Date
NO920854D0 NO920854D0 (no) 1992-03-04
NO920854L true NO920854L (no) 1992-04-27

Family

ID=22215208

Family Applications (2)

Application Number Title Priority Date Filing Date
NO92920854A NO920854L (no) 1989-09-05 1992-03-04 Fremgangsmaate og sammensetninger for ikke-invasiv dose til effekt-administrering av lipofile medikamenter
NO92920855A NO920855L (no) 1989-09-05 1992-03-04 Medikamentinneholdende matrise

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO92920855A NO920855L (no) 1989-09-05 1992-03-04 Medikamentinneholdende matrise

Country Status (8)

Country Link
EP (1) EP0493380B1 (de)
JP (1) JP2758985B2 (de)
AT (1) ATE159658T1 (de)
AU (2) AU645966B2 (de)
DE (1) DE68928415T2 (de)
DK (1) DK175773B1 (de)
NO (2) NO920854L (de)
WO (1) WO1991003233A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH624011A5 (de) * 1977-08-05 1981-07-15 Battelle Memorial Institute
EP0745380B1 (de) * 1995-05-11 2005-08-03 University Of Utah Research Foundation Tabakersatz
US20060051413A1 (en) * 2004-09-08 2006-03-09 Chow Sing S M Method of enhancing absorptions of transmucosal administration formulations
US7776831B2 (en) * 2006-02-01 2010-08-17 Weg Stuart L Use of antifungal compositions to treat upper gastrointestinal conditions
US20160022643A1 (en) * 2014-07-22 2016-01-28 Professional Compounding Centers Of America Oral Transmucosal Compositions including Aromatase Inhibitors for Low Testosterone Levels in Men
US10525099B2 (en) 2014-10-01 2020-01-07 Oxytone Bioscience B.V. Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance
HUE051974T2 (hu) 2014-10-01 2021-04-28 Oxytone Bioscience B V Szájban szétesõ, szülést szabályozó ágenst tartalmazó, szilárd halmazállapotú gyógyászati dózisegység
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955918A1 (de) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Verfahren zur behandlung neurokognitiver störungen, chronischer schmerzen und verringerung von entzündung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2208120A (en) * 1938-03-02 1940-07-16 William B Coleman Pharmaceutical preparation and method of making same
US3943928A (en) * 1974-09-25 1976-03-16 Lariccia Anthony H Eliminating the safety hazard in oral dissolution of a solid
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4551329A (en) * 1984-01-20 1985-11-05 Joan Harris Oral medicament lollipop
US4671953A (en) * 1985-05-01 1987-06-09 University Of Utah Research Foundation Methods and compositions for noninvasive administration of sedatives, analgesics, and anesthetics

Also Published As

Publication number Publication date
AU6069794A (en) 1994-06-23
DK30092D0 (da) 1992-03-05
EP0493380A1 (de) 1992-07-08
WO1991003233A1 (en) 1991-03-21
NO920855D0 (no) 1992-03-04
DK175773B1 (da) 2005-02-14
DE68928415D1 (de) 1997-12-04
EP0493380B1 (de) 1997-10-29
AU645966B2 (en) 1994-02-03
JP2758985B2 (ja) 1998-05-28
ATE159658T1 (de) 1997-11-15
DE68928415T2 (de) 1998-02-26
EP0493380A4 (en) 1992-10-07
NO920855L (no) 1992-04-10
DK30092A (da) 1992-05-05
NO920854D0 (no) 1992-03-04
AU5035290A (en) 1991-04-08
JPH05501854A (ja) 1993-04-08

Similar Documents

Publication Publication Date Title
Kennedy et al. Intravenous regional analgesia: an appraisal
SE9401406L (sv) Farmaceutiska produkter för att bota tumörsjukdomar samt förfarande för framställning av desamma
ATE113203T1 (de) Darreichnungsform zur verabreichnung eines antiparkinsonsmittel.
DE69003392T2 (de) Dosisform zur oralen verabreichung des hypoglykämischen glipizids.
HK18695A (en) Inhalation medicaments for treating respiratory disorders
DE69002718T2 (de) Medikamente.
JPH05504546A (ja) 痛みのある疾患又はアレルギー性疾患の治療用組成物及び治療法
NO920854L (no) Fremgangsmaate og sammensetninger for ikke-invasiv dose til effekt-administrering av lipofile medikamenter
Aldrete et al. Reverse carotid blood flow—a possible explanation for some reactions to local anesthetics
Bloom et al. Clinical evaluation of prazosin as the sole agent for the treatment of hypertension: A double-blind cross-over study with methyldopa.
Hultgren et al. Clinical and experimental study of use of khellin in treatment of angina pectoris
Smith, LR, Potgieter, PD & Chappell Scorpion sting producting severe muscular paralysis-a case report
Clement Effect of indoramin on finger blood flow in vasospastic patients
Frithz Once-daily treatment of hypertension
Reynolds et al. Circulatory versus respiratory deaths from pentothal sodium
CN2233753Y (zh) 护心袋
RU94018748A (ru) Лекарственный сбор для лечения больных с нарушениями сердечного ритма
Wilbert Drug Intoxication: An Economic Waste and a Menace to Public Health
RU94019564A (ru) Способ лечения желудочно-кишечных заболеваний
Woods Sedation for dental treatment of infants. I. Physiology and pharmacology
CN1174914A (zh) 防治呼吸道疾病的药物纸巾
Woods Sedation for dental treatment of infants. II. Clinical procedure
王小马 ELECTROIMPULSE ACUPUNCTURE TREATMENT OF 110 CASES OF ABDOMINAL PAIN AS A SEOUELA OF ABDOMINAL SURGERY
Samuels et al. Regional anesthesia for the emergency department physician
Blower Posts in clinical rheumatology